Unraveling the Puzzle: Oocyte Maturation Abnormalities (OMAS)
Safak Hatirnaz,
Ebru Hatirnaz,
Samettin Çelik,
Canan Soyer Çalışkan,
Andrea Tinelli,
Antonio Malvasi,
Radmila Sparic,
Domenico Baldini,
Michael Stark,
Michael H. Dahan
Affiliations
Safak Hatirnaz
Mediliv Medical Center, Samsun 55100, Turkey
Ebru Hatirnaz
Mediliv Medical Center, Samsun 55100, Turkey
Samettin Çelik
Department of Obstetrics and Gynecology, Samsun Training and Research Hospital, Samsun 55090, Turkey
Canan Soyer Çalışkan
Department of Obstetrics and Gynecology, Samsun Training and Research Hospital, Samsun 55090, Turkey
Andrea Tinelli
Department of Obstetrics and Gynecology and CERICSAL (CEntro di RIcercaClinicoSALentino), Verisdelli Ponti Hospital, 73020 Scorrano, Italy
Antonio Malvasi
Department of Biomedical Sciences and Human Oncology, Obstetrics and Gynecology Section, University of Bari “Aldo Moro”, Piazza Aldo Moro, 70100 Bari, Italy
Radmila Sparic
Medical Faculty, Clinic for Gynecology and Obstetrics, University Clinical Center of Serbia, University of Belgrade, 11000 Belgrade, Serbia
Domenico Baldini
MomòFertilife Clinic, 76011 Bisceglie, Italy
Michael Stark
The New European Surgical Academy (NESA), 10117 Berlin, Germany
Michael H. Dahan
McGill University Health Center Reproductive Centre, Department of ObGyn, McGill University, Montreal, QC H3A 0G4, Canada
Oocyte maturation abnormalities (OMAS) are a poorly understood area of reproductive medicine. Much remains to be understood about how OMAS occur. However, current knowledge has provided some insight into the mechanistic and genetic origins of this syndrome. In this study, current classifications of OMAS syndromes are discussed and areas of inadequacy are highlighted. We explain why empty follicle syndrome, dysmorphic oocytes, some types of premature ovarian insufficiency and resistant ovary syndrome can cause OMAS. We discuss live births in different types of OMAS and when subjects can be offered treatment with autologous oocytes. As such, we present this review of the mechanism and understanding of OMAS to better lead the clinician in understanding this difficult-to-treat diagnosis.
